Reading an interaction checker output critically posts 121–150
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to interactions. There is no pharmacokinetic interaction of concern.
Worth saying I have only my own numbers here, and n is small.
Distinguishing three things in the reading an interaction checker output discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
Worth separating two things that post #122 runs together.
The most defensible general position in this subcategory: identify the plausible mechanism, check whether it has been studied, and where it has not, say that rather than filling the gap.
This follows post #125 rather than contradicting it.
Trying to state the reading an interaction checker output position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.
Anything that also slows gut motility compounds the same mechanism. That is a plausibility argument rather than a documented interaction, and it should be labelled as one.
That is what I would do. It may not be what is correct.
Research-use-only compounds have no interaction data of any kind, because interaction studies are done on medicines being developed for use in people.
Two claims get bundled together under reading an interaction checker output and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one — this is why — usually is not.
Almost every disagreement in threads like this one dissolves once you say which of the two you are making.
Renal or hepatic impairment changes the calculus for a lot of combinations and is the context most often missing from an interaction question here.
A supplement is a drug for interaction purposes, and the fact that it is sold without a prescription tells you nothing about whether it interacts. The paperwork is usually worse rather than better.
I would treat that as a working assumption and revisit it.
On post #130 — agreed on the reasoning, with one qualification.
Supplements and herbs: many have no established interaction. Some do. If you are taking something unusual, checking a reference (like a pharmacist) is more useful than guessing from forum discussion.
That distinction has done more work for me than anything else in this category.
Collapsed as off-topic by two members at trust level 3 or above
Alcohol is not contraindicated in the labelling and it does irritate a stomach that is already emptying slowly. There is no published interaction study, and the conservative reading is the obvious one.
I would treat the number as indicative rather than as a measurement.
Absence of an interaction study is not evidence of no interaction. A great many combinations discussed here have simply never been studied, and saying so is more useful than reasoning from mechanism alone.
I have written this out at length because the short version keeps being misread.
Confirming post #136 from a second method, which matters more than confirming it from a second person.
Nothing here is medical advice and an interaction question is one where the cost of a wrong forum answer is genuinely high. Ask the prescriber or the pharmacist.
Vitamins: most vitamins have no significant interaction. Fat-soluble vitamins (A, D, E, K) might be affected by the slowing of fat absorption during weight loss, but that is a nutritional consequence rather than an interaction.
Post #139 put the caveat in the right place and I want to underline it.
If you are new and reading this thread for the answer to reading an interaction checker output: the answer is conditional, the conditions are in the third reply, and the rest of the thread is worth skipping.
Building on post #139 rather than restating it.
Where a published interaction study exists it usually reports an area-under-curve ratio, and that number is far more informative than a yes-or-no answer.
I would hold that lightly until someone with a larger sample weighs in.
Anticoagulants: no direct interaction with the compounds in this class. Weight loss and body composition changes might affect the clearance or effect of warfarin if you are on it; monitoring INR more frequently during weight loss is reasonable.
This is the sort of thing that ought to be settled and apparently is not.
Adding a data point of agreement rather than a data point.
Post #143 is the version of this I will quote in future. One addition.
Insulin and sulfonylureas are the interaction that the labelling in this class flags most explicitly, because the risk is additive glucose lowering. That is a prescribing question and not a forum question.
Post #143 describes the usual case. This is about the unusual one.
Reframing reading an interaction checker output slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.
The most defensible general position in this subcategory: identify the plausible mechanism, check whether it has been studied, and where it has not, say that rather than filling the gap.
The reasoning is more useful than the number, which is why I have shown it.
Insulin interaction: semaglutide and tirzepatide are not contraindicated with insulin but the combination carries hypoglycemia risk if insulin doses are not adjusted. That is a reason for close monitoring, not for avoiding the combination.
Someone will know this better than I do and I hope they say so.